Sanfetrinem cilexetil | 141646-08-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 内酰胺类
• 英文名称: Sanfetrinem cilexetil
• 英文别名: 1-cyclohexyloxycarbonyloxyethyl (1S,5S,8aS,8bR)-1-[(1R)-1-hydroxyethyl]-5-methoxy-2-oxo-5,6,7,8,8a,8b-hexahydro-1H-azeto[1,2-b]isoindole-4-carboxylate
• CAS: 141646-08-4
• 化学式: C₂₃H₃₃NO₈
• 分子量: 451.5
• InChiKey: QFEICXCLIGZEJB-IRVPUMQPSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  32
• 可旋转键数：
  9
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.78
• 拓扑面积：
  112
• 氢给体数：
  1
• 氢受体数：
  8

文献信息

• Novel Lipopeptides as Antibacterial Agents
  申请人：Hill Jason

  公开号：US20090011977A1

  公开（公告）日：2009-01-08

  The present invention relates to novel lipopeptide compounds. The invention also relates to pharmaceutical compositions of these compounds and methods of using these compounds as antibacterial compounds. The invention also relates to methods of producing these novel lipopeptide compounds and intermediates used in producing these compounds.

  本发明涉及新型脂肽化合物。本发明还涉及这些化合物的药物组合物以及将这些化合物用作抗菌化合物的方法。本发明还涉及生产这些新型脂肽化合物的方法以及用于生产这些化合物的中间体。
• Sanfetrinem or a salt or ester thereof for use in treating mycobacterial infection
  申请人：GlaxoSmithKline Intellectual Property Development Limited

  公开号：US11253500B2

  公开（公告）日：2022-02-22

  The present invention relates to or a pharmaceutically acceptable salt or ester prodrug thereof for use in the treatment of a mycobacterial infection or disease resulting from a mycobacterial infection, such as tuberculosis.

  本发明涉及或其药学上可接受的盐或酯原药，用于治疗分枝杆菌感染或分枝杆菌感染引起的疾病，如结核病。
• SANFETRINEM OR A SALT OR ESTER THEREOF FOR USE IN TREATING MYCOBACTERIAL INFECTION
  申请人：GlaxoSmithKline Intellectual Property Development Limited

  公开号：US20200289462A1

  公开（公告）日：2020-09-17

  The present invention relates to or a pharmaceutically acceptable salt or ester prodrug thereof for use in the treatment of a mycobacterial infection or disease resulting from a mycobacterial infection, such as tuberculosis.
• US8557979B2
  申请人：——

  公开号：US8557979B2

  公开（公告）日：2013-10-15